Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
Date:11/1/2011

LYNBROOK, N.Y., Nov. 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 8, 2011 to report its third quarter 2011 financial results and provide a corporate update.

In order to participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=83154.

A replay of the call will be available one hour after the end of the conference on November 8, 2011 until 9:00 a.m. EST on November 18, 2011. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 10005920. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease which is currently in Phase 3 pivotal clinical trials, frozen shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
2. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
4. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
5. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
6. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
7. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
9. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... , ... July 17, 2017 , ... ... Weihong Hsing, Ph.D. , recently participated in the BiG (Biomedical Innovation Group) annual ... dominated by discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Extreme Environment Shakers today. ... that require CO2 and humidity for optimal cell growth such as cell cultures, ...
(Date:7/14/2017)... (PRWEB) , ... July 13, 2017 , ... ... linearity and calibration verification test kit has received US FDA 510 (k) clearance ... a human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical ... has announced today the completion of a major transaction with Eurazeo PME. The ... external growth. The alliance fuels In’Tech Medical’s service offerings while leveraging the company’s ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):